TY - JOUR
T1 - Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1+ mouse BA/F3 cells
AU - von Palffy, Sofia
AU - Bulaeva, Elizabeth
AU - Babovic, Sonja
AU - Kannan, Nagarajan
AU - Knapp, David J.H.F.
AU - Wei, Lisa
AU - Eaves, Connie J.
AU - Beer, Philip A.
N1 - Publisher Copyright:
© 2015.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Inactivating mutations in IKZF1, the gene that encodes the transcription factor IKAROS, are recurrent in poor-prognosis human B-cell leukemias, in which these mutations co-exist with BCR-ABL1 or other genetic changes that activate similar intracellular signaling pathways. However, little is known about the mechanism(s) by which loss of IKAROS activity may co-operate with BCR-ABL1 to transform lymphoid cells. To investigate this question, we used expression of a dominant-negative isoform of IKAROS (IK6) to suppress endogenous IKAROS activity in the interleukin-3 (IL-3)-dependent mouse pro-B BA/F3 cell line and in an IL-3-independent BCR-ABL1+ derivative. We then used intracellular phospho-flow cytometry to assess the effects of BCR-ABL1 and IK6, alone and in combination, on the signaling state of the cells before and after their stimulation with IL-3. BCR-ABL1 and IK6 each produced a constitutively activated signaling phenotype and also enhanced the signaling responses of BA/F3 cells to IL-3. These effects, however, were neither equivalent nor additive, and IK6 alone was insufficient to confer the IL-3-independent growth characteristic of BCR-ABL1+ BA/F3 cells. In addition to its effects on lymphoid cells, IK6 also induced constitutively activated signaling in a subset of myeloid leukemia cell lines. Together, these studies indicate an ability of IK6 to enhance intracellular signaling in both lymphoid and myeloid cells, but not to synergize with BCR-ABL1 in this model system.
AB - Inactivating mutations in IKZF1, the gene that encodes the transcription factor IKAROS, are recurrent in poor-prognosis human B-cell leukemias, in which these mutations co-exist with BCR-ABL1 or other genetic changes that activate similar intracellular signaling pathways. However, little is known about the mechanism(s) by which loss of IKAROS activity may co-operate with BCR-ABL1 to transform lymphoid cells. To investigate this question, we used expression of a dominant-negative isoform of IKAROS (IK6) to suppress endogenous IKAROS activity in the interleukin-3 (IL-3)-dependent mouse pro-B BA/F3 cell line and in an IL-3-independent BCR-ABL1+ derivative. We then used intracellular phospho-flow cytometry to assess the effects of BCR-ABL1 and IK6, alone and in combination, on the signaling state of the cells before and after their stimulation with IL-3. BCR-ABL1 and IK6 each produced a constitutively activated signaling phenotype and also enhanced the signaling responses of BA/F3 cells to IL-3. These effects, however, were neither equivalent nor additive, and IK6 alone was insufficient to confer the IL-3-independent growth characteristic of BCR-ABL1+ BA/F3 cells. In addition to its effects on lymphoid cells, IK6 also induced constitutively activated signaling in a subset of myeloid leukemia cell lines. Together, these studies indicate an ability of IK6 to enhance intracellular signaling in both lymphoid and myeloid cells, but not to synergize with BCR-ABL1 in this model system.
UR - http://www.scopus.com/inward/record.url?scp=84930794800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930794800&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2015.04.004
DO - 10.1016/j.exphem.2015.04.004
M3 - Article
C2 - 25951974
AN - SCOPUS:84930794800
SN - 0301-472X
VL - 43
SP - 514-523.e2
JO - Experimental Hematology
JF - Experimental Hematology
IS - 7
ER -